Analysts expect Danaher Co. (NYSE:DHR) to post $5.32 billion in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Danaher’s earnings, with the lowest sales estimate coming in at $5.26 billion and the highest estimate coming in at $5.41 billion. Danaher posted sales of $5.09 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 4.5%. The company is expected to announce its next quarterly earnings results on Tuesday, January 29th.

On average, analysts expect that Danaher will report full year sales of $19.84 billion for the current financial year, with estimates ranging from $19.79 billion to $19.93 billion. For the next year, analysts anticipate that the firm will post sales of $20.54 billion, with estimates ranging from $20.15 billion to $20.79 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Danaher.

Danaher (NYSE:DHR) last released its quarterly earnings data on Thursday, October 18th. The conglomerate reported $1.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.03. Danaher had a net margin of 14.07% and a return on equity of 11.59%. The business had revenue of $4.85 billion during the quarter, compared to analyst estimates of $4.80 billion. During the same quarter last year, the business earned $1.00 earnings per share. Danaher’s quarterly revenue was up 7.2% compared to the same quarter last year.

Several research firms have recently issued reports on DHR. Zacks Investment Research upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $119.00 target price for the company in a report on Wednesday, September 19th. Morgan Stanley raised their target price on shares of Danaher from $122.00 to $126.00 and gave the stock an “overweight” rating in a report on Wednesday, October 10th. Finally, Robert W. Baird lowered their target price on shares of Danaher from $116.00 to $114.00 and set an “outperform” rating for the company in a report on Friday, October 19th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Danaher has a consensus rating of “Buy” and a consensus price target of $112.14.

DHR stock traded up $0.67 during trading on Thursday, hitting $101.97. 2,682,974 shares of the company’s stock traded hands, compared to its average volume of 2,432,101. The firm has a market capitalization of $72.33 billion, a P/E ratio of 25.30, a price-to-earnings-growth ratio of 1.99 and a beta of 1.04. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38. Danaher has a 52 week low of $91.84 and a 52 week high of $110.13.

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 26th. Investors of record on Friday, September 28th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $0.64 dividend on an annualized basis and a yield of 0.63%. Danaher’s payout ratio is 15.88%.

In related news, SVP Robert S. Lutz sold 15,000 shares of Danaher stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $103.80, for a total transaction of $1,557,000.00. Following the completion of the sale, the senior vice president now owns 33,044 shares in the company, valued at approximately $3,429,967.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas Patrick Joyce, Jr. sold 5,212 shares of Danaher stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $541,474.68. Following the sale, the insider now owns 151,829 shares of the company’s stock, valued at approximately $15,773,514.81. The disclosure for this sale can be found here. Insiders have sold a total of 150,007 shares of company stock valued at $15,202,163 in the last quarter. 11.90% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in DHR. Mitchell Capital Management Co. increased its position in Danaher by 31.6% during the 2nd quarter. Mitchell Capital Management Co. now owns 7,962 shares of the conglomerate’s stock valued at $786,000 after purchasing an additional 1,914 shares during the period. Private Wealth Partners LLC increased its position in Danaher by 14.3% during the 2nd quarter. Private Wealth Partners LLC now owns 95,800 shares of the conglomerate’s stock valued at $9,454,000 after purchasing an additional 11,961 shares during the period. Centaurus Financial Inc. increased its position in Danaher by 20.3% during the 2nd quarter. Centaurus Financial Inc. now owns 3,026 shares of the conglomerate’s stock valued at $299,000 after purchasing an additional 510 shares during the period. Bainco International Investors increased its position in Danaher by 2.6% during the 3rd quarter. Bainco International Investors now owns 66,878 shares of the conglomerate’s stock valued at $7,267,000 after purchasing an additional 1,725 shares during the period. Finally, First Midwest Bank Trust Division increased its position in Danaher by 18.2% during the 3rd quarter. First Midwest Bank Trust Division now owns 6,462 shares of the conglomerate’s stock valued at $702,000 after purchasing an additional 993 shares during the period. Institutional investors own 77.31% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.

See Also: Marijuana Stocks

Get a free copy of the Zacks research report on Danaher (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.